Dr. Bhave on Promising Combination Strategies in TNBC

Video

In Partnership With:

Manali Bhave, MD, discusses promising combination strategies in triple-negative breast cancer.

Manali Bhave, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, medical oncologist, Winship Cancer Institute, discusses promising combination strategies in triple-negative breast cancer (TNBC).

Scientific rationale suggests that adding targeted therapies to immunotherapy could enhance neoantigen expression and enhance the efficacy of immunotherapy in patients with TNBC, says Bhave.

Moreover, combinations of targeted therapy and immunotherapy may yield less toxicity vs chemotherapy and could, improve quality of life for this patient population, concludes Bhave.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD